As of November 10, 2026, Terns Pharmaceuticals, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 14 filings are on record since August 14, 2025 (Schedule 13G/A, June 5, 2026).
Sell to companies like Terns Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-06-05
- · Holder: Adage Capital Management, L.P. · Percent: 1.84% · SCHEDULE 13G/A
- · Holder: Morgan Stanley · Percent: 5.6% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: Commodore Capital LP · Percent: 1.4% · SCHEDULE 13G/A
Terns Pharmaceuticals, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 4.8% | 4,240,068 | SCHEDULE 13D/A, 2025-11-05 | 2025-11-03 |
| Deep Track Capital, LP | 2.97% | 3,150,000 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | 2,700,615 | SCHEDULE 13G/A, 2026-02-13 | 2025-01-31 |
| Adage Capital Management, L.P. | 1.84% | 2,124,817 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| Commodore Capital LP | 1.4% | 1,475,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Soleus Capital Master Fund, L.P. | 0.2% | 212,710 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| 0% | 0 | SCHEDULE 13G/A, 2026-06-05 | 2026-05-31 |
Holding shares or following this stake? See who's behind Terns Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Terns Pharmaceuticals, Inc. and the records around it.
Companies that share a holder
- Vivo Capital Fund VIII, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Terns Pharmaceuticals, Inc.
Get an email when Terns Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Terns Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Terns Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Terns Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Morgan Stanley | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-06-05 |
The latest filing identifies Terns Pharmaceuticals, Inc. by CUSIP 880881107 and gives its principal executive office as 1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA 94404 (SCHEDULE 13G/A, 2026-06-05).
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Amendment No. 6, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-05; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Deep Track Capital, LP | 8.58% | SCHEDULE 13G/A |
| 2025-09-16 | Commodore Capital LP | 5.3% | SCHEDULE 13G |
| 2025-10-31 | The Vanguard Group | 5.21% | SCHEDULE 13G |
| 2025-11-05 | Orbimed Advisors LLC | 4.8% | SCHEDULE 13D/A |
| 2025-11-14 | Commodore Capital LP | 6.5% | SCHEDULE 13G/A |
| 2026-02-12 | Adage Capital Management, L.P. | 5.1% | SCHEDULE 13G |
| 2026-02-12 | Soleus Capital Master Fund, L.P. | 0.2% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 2.97% | SCHEDULE 13G/A |
| 2026-02-13 | Vivo Opportunity Fund Holdings, L.P. | 2.5% | SCHEDULE 13G/A |
| 2026-02-17 | Commodore Capital LP | 1.4% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-12 | Morgan Stanley | 5.6% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 1.84% | SCHEDULE 13G/A |
| 2026-06-05 | Morgan Stanley | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Terns Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.